Baidu
map

JAHA:Fontan手术后肝癌的发病率、预测指标和死亡率

2021-02-06 MedSci原创 MedSci原创

在Fontan手术30年后,LC的发生率迅速增加,肝纤维化指标和AFP可作为新发LC的预测指标。应严格监控这些LC预测标记物,以尽早发现LC和改善患者预后。

Fontan手术后,肝癌(LC)是严重的晚期并发症。但是,其发病率、预测因素和预后仍然未知。

近日,血管疾病领域权威杂志JAHA上发表了一篇研究文章,研究人员旨在明确这些患者的临床特征。研究人员评估了2005年至2019年期间接受过Fontan手术的339例患者的肝功能。

在中位时间为2.9年的随访期间,有10例患者在组织学上诊断为LC(范围:0.3-13.8;中位年龄为29.9岁[范围为14.4-41.5岁];Fontan手术后随访年龄的总体中位数为25.6岁[范围:13-32.1岁]),LC年发病率为0.89%。在整个Fontan术后随访期间,第二、第三和第四个十年的新发LC的年发病率分别为0.14%、0.43%和8.83%。LC患者的随访时间较长,AFP(甲胎蛋白)水平较高,肝纤维化指数值较高(P<0.01–0.0001)。此外,所有指标均可预测新发LC(P<0.01–0.0001)。LC治疗包括手术切除(n=3)、经动脉化学栓塞(n=3)、射频消融(n=2)和临终关怀(n=2)。在9.4个月的中位随访期间,有4例患者死亡。1年生存率为60%,无症状患者生存率更好(P <0.01)。

由此可见,在Fontan手术30年后,LC的发生率迅速增加,肝纤维化指标和AFP可作为新发LC的预测指标。应严格监控这些LC预测标记物,以尽早发现LC和改善患者预后

原始出处:

Hideo Ohuchi.et al.Incidence, Predictors, and Mortality in Patients With Liver Cancer After Fontan Operation.J AM HEART ASSOC.2021.https://www.ahajournals.org/doi/full/10.1161/JAHA.120.016617

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-08 zhaohui6731
  4. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-08 xuyu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-06 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1823700, encodeId=85d41823e0067, content=<a href='/topic/show?id=b2873e9220e' target=_blank style='color:#2F92EE;'>#发病率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37922, encryptionId=b2873e9220e, topicName=发病率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=aa0e14, createdName=lifestar, createdTime=Fri Feb 12 11:11:04 CST 2021, time=2021-02-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1699980, encodeId=3312169998040, content=<a href='/topic/show?id=e720e583c0' target=_blank style='color:#2F92EE;'>#Fontan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7583, encryptionId=e720e583c0, topicName=Fontan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=284729986400, createdName=changjitao2019, createdTime=Thu Aug 05 18:11:04 CST 2021, time=2021-08-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1268411, encodeId=7deb1268411cc, content=<a href='/topic/show?id=922f21183d' target=_blank style='color:#2F92EE;'>#AHA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2118, encryptionId=922f21183d, topicName=AHA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bf3d82, createdName=zhaohui6731, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1407055, encodeId=1604140e0557a, content=<a href='/topic/show?id=fa7c100231a5' target=_blank style='color:#2F92EE;'>#预测指标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=100231, encryptionId=fa7c100231a5, topicName=预测指标)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10c72588657, createdName=anminleiryan, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1629150, encodeId=2b7e1629150ce, content=<a href='/topic/show?id=a196e586d4' target=_blank style='color:#2F92EE;'>#Fontan手术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7586, encryptionId=a196e586d4, topicName=Fontan手术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22fb21322530, createdName=xuyu, createdTime=Mon Feb 08 01:11:04 CST 2021, time=2021-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040355, encodeId=0d9c104035574, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Feb 06 13:11:04 CST 2021, time=2021-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=923241, encodeId=697792324115, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b192480386, createdName=用户被禁用, createdTime=Sat Feb 06 13:06:15 CST 2021, time=2021-02-06, status=1, ipAttribution=)]
    2021-02-06 用户被禁用

    学习了

    0

相关资讯

25岁女子查出肝癌!这一习惯成“罪魁祸首”

小芬(化名)今年25岁,家住宝安,在一家IT企业上班。8月她到医院体检时,被检查出肝右前叶有肿块,复查被初步确诊为肝癌和肝硬化。据了解,小芬10年前患上乙肝。医生表示,熬夜加上不健康的生活方式,都是慢

Br J Cancer:抑制CBX4可有效抑制肝癌细胞索拉非尼耐药性的产生

肝细胞癌(HCC)作为全球第三大癌症相关死亡主要原因(占所有癌症相关死亡的8.2%),其发病率逐年上升且具有较高的死亡率。

Hepatol Int:术前即可预测肝癌患者术后6个月内死亡率的个体化模型!

术前就能知道术后有多大的概率会死,就可以更好的决定要不要做手术了

J Hepatol:肝细胞NRF2特异性激活调控肝纤维化和肝癌的发生

KEAP1/NRF2系统在肝纤维化和肝癌的发生发展中有什么样的作用呢?

Dig Dis Sci: 羟基类固醇17-β脱氢酶6(HSD17β6)是一种肝细胞癌的免疫浸润相关预后性生物标志物

肝细胞癌(HCC)是世界上最常见的致死性癌症之一,据统计,全世界每年约有70万人死于肝癌。

Baidu
map
Baidu
map
Baidu
map